Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Locations: - Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
+ 1226 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Locations: - NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
+ 277 more sites in the U.S.
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Locations: - Pioneer Research Center — Bullhead City, Arizona
- Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
+ 223 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Locations: - Tower Cancer Research Foundation — Beverly Hills, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Cedars-Sinai Cancer - Tarzana — Tarzana, California
+ 97 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Locations: - Clearview Cancer Institute — Huntsville, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Banner University Medical Center Phoenix — Phoenix, Arizona
+ 84 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Locations: - Research Site — Tucson, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Anaheim, California
+ 74 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
+ 68 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Locations: - Local Institution - 0487 — Mobile, Alabama
- Southern Arizona VA Health Care System — Tucson, Arizona
- Local Institution - 0112 — Los Angeles, California
+ 53 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Locations: - Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0163) — Tucson, Arizona
- Providence St. Jude Medical Center ( Site 0106) — Fullerton, California
+ 51 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Locations: - Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology — Birmingham, Alabama
- Alaska Oncology and Hematology, LLC — Anchorage, Alaska
- John Muir Clinical Research Center — Concord, California
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT04928846
Locations: - University of Alabama at Birmingham - Main /ID# 247074 — Birmingham, Alabama
- Ironwood Cancer & Res Ctr /ID# 262446 — Chandler, Arizona
- Mayo Clinic Arizona /ID# 255858 — Phoenix, Arizona
+ 47 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Locations: - Southern Cancer Center Pc — Daphne, Alabama
- Mohtaseb Cancer Center & Blood Disorders — Bullhead City, Arizona
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 38 more sites in the U.S.